Analysing lymphokine-receptor interactions of IL-1 and IL-2 by recombinant-DNA technology.
The development of lymphokines as pharmaceutical agents is at the forefront of current biotechnological research. Lymphokines exert their regulatory action on cellular function through interaction with cell-surface receptors. An understanding of the biochemical nature of these molecular interactions should facilitate the design of small peptide analog pharmaceuticals which mimic lymphokines or their receptors.
Zurawski
G
G
DNAX Research Institute of Molecular and Cellular Biology Inc., Palo Alto, CA 94304-1104.
D000595:Amino Acid Sequence; D000818:Animals; D004274:DNA, Recombinant; D006801:Humans; D007375:Interleukin-1 / Q000235:genetics / Q000378:metabolism*; D007376:Interleukin-2 / Q000235:genetics / Q000378:metabolism*; D008969:Molecular Sequence Data; D016296:Mutagenesis; D011971:Receptors, Immunologic / Q000235:genetics / Q000378:metabolism*; D017472:Receptors, Interleukin-1; D015375:Receptors, Interleukin-2 / Q000235:genetics / Q000378:metabolism*
D004274:DNA, Recombinant; D007375:Interleukin-1; D007376:Interleukin-2; D011971:Receptors, Immunologic; D017472:Receptors, Interleukin-1; D015375:Receptors, Interleukin-2